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Differential Properties Of Stromal Cells From Bone
Marrow, Adipose, Cardiac and Liver
Ian McNiece 1, Santhosh Sivajothi 2. 1 Stem Cell Transplantation
and Cellular Therapy, MD Anderson Cancer Center, Houston,
TX; 2 The UNiversity of Texas MD Anderson Cancer Center,
Houston, TX
Bone marrow (BM) stromal cells (also termed mesenchymal
stem cells; MSC) have been extensively studied and shown to
control differentiation of hematopoietic stem cells (HSCs) in
part through secreted growth factors. In addition, MSCs
support the growth of tumor cells both in vitro and in vivo.
As MSCs are being evaluated in a number of clinical trials for
regenerative medicine approaches, it is critical to understand
the role of stromal cells in different tissues. Stromal cells
were isolated from various human tissues including adipose
(Ad), cardiac (Car) and liver (Liv) tissues as well as bone
marrow (BM) and had an identical appearance in culture. We
have compared the stromal cells from these tissues and
demonstrate that although they have similar morphology
and surface marker expression (CD105+/CD90+/CD73+ and
CD45-/CD34-) they have differential biological properties.
BM MSCs have been shown previously to support both
normal hematopoietic cells and tumor cells.
To test the functional properties of the stromal cell lines we
co-cultured stromal cells with either cord blood (CB) cells or
tumor cells (K562). As we have previously reported, co-cul-
ture of CB on BM-MSCs resulted in expansion of hemato-
poietic cells. Similarly, Ad stromal cells supported expansion
of hematopoietic cells, however, Liv and Car stromal cells
failed to expand the CB cells. The effect of the Car stromawas
through a cytostatic mechanism as removal of the CB cells
from the stromal cells after 7 days of co-culture resulted
in hematopoietic cell expansion and detection of colony
forming cells by methycellulose assay. We also tested the
potential of the stromal cells to support tumor cell growth by
co-culturing K562 cells with the stromal cells. Ad and Liv
stroma supported growth of the K562 cells similar to BM
MSCs, while Car stromal cells inhibited K562 cell growth
with few viable cells after 7 days of culture.
These data suggest that the function of stromal cells from
different tissue is variable. In particular, tumor development
in cardiac tissue is a rare event and our data suggest that Car
stromal cells may play a key role in inhibiting proliferation of
tumor cells. Further we propose that non homologous use of
stromal cells in clinical applications may have deleterious
effects, for example the use of BM-MSCs to repair ischemic
tissue in the heart may lead to a tumor supportive environ-
ment in cardiac tissue.
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Development of Conditioning Regimens Based on HSC-
Targeted Antibody ACK2
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Xingkui Xue 4, Erin Breese 5, Mervin Yoder 6. 1 Department of
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Hematology/Oncology, Stanford University School of Medicine,
Palo Alto, CA; 6 Indiana University Cancer Research Institute,
Indianapolis, INBackground: Marrow conditioning prior to HSC trans-
plantation incorporates chemotherapy and/or radiotherapy
to eradicate malignant disease, eliminate immunologic
barriers to allogeneic cell engraftment, and to ‘make space’
for donor HSC within the HSC niche. The sequelae of such
treatments can be substantial, including direct organ
toxicity. Selective targeting of HSC with monoclonal anti-
bodies presents an alternative approach to induce stem cell
depletion with fewer off target effects. Previous studies in a
congenic mouse transplant model established that anti-
body-mediated blockade of c-Kit, the receptor for stem cell
factor, given in combination with low dose irradiation
(LD-IR) efﬁciently depletes HSC and substantially enhances
engraftment of donor HSC in immunocompetent mice (Xue
et al, Blood 2010). However, since even low doses of irra-
diation have long-term risks, particularly in children, an
important goal is to develop improved regimens utilizing
c-Kit blockade.
Objective: To determine if replacing low dose irradiation
(LD-IR) with chemotherapy will synergize with c-Kit
blockade and improve engraftment in a congenic mouse
transplant model.
Methods: Mice were transplanted according to standard
protocol. C57B6 (CD45.2) mice were used as donors, and F1
progeny of C57B6 and BoyJ mice (CD45.1) were used as
recipients. Recipient mice were treated with 2 mg of the KIT-
blocking monoclonal antibody ACK2 (injected intraperito-
neally) combined with various schedules of Fludarabine
100mg/kg IP / Cyclophosphamide 200mg/kg IP (FluCy); or
5-ﬂurouracil (5-FU )150 mg/kg IP; or Busulfan (Bu) 20mg/kg
IP. Control mice were treated with the ACK2 and 300 cGy.
This was followed by transplantation of 1- 2 million freshly
isolated congenic marrow cells and subsequent long-term
engraftment analysis by ﬂow cytometry.
Results: In comparison to ACK2/LD-IR, the level of engraft-
ment post-transplant was much lower in all of the other
treatment arms. ACK2/FluCy had < 5% engraftment at 13
weeks compared to 80% engraftment in the ACK2/LD-IR arm.
ACK2/Bu had < 5% engraftment compared to 70% in the
ACK2/LD-IR arm at 20 weeks and ACK2/5-FU had < 5%
compared to 80% engraftment at 13 weeks in the ACK2/LDR
arm.
Conclusion: Our study demonstrates that combination of
antibody-mediated c-Kit blockade and chemotherapy did
not enhance congenic donor cell engraftment, at least in the
regimens tested. Further experiments to elucidate how LD-IR
and c-Kit blockade synergize to deplete HSCs and enhance
engraftment are ongoing.277
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Abstracts / Biol Blood Marrow Transplant 20 (2014) S184eS210S188Background: Cryopreserved cord blood units (CBU) provide
a source of donor hematopoietic stem cells for trans-
plantation for patients in need of a suitable donor. Primary
graft failures and delayed engraftment occur in up to
10-15% of patients following cord blood (CB) transplant
which may be due to low potency, deﬁned as low levels of
viable engrafting hematopoietic stem and progenitor cells.
The majority of transplant centers currently select CBUs for
their patients based on HLA match, pre-cryopreservation
total nucleated cell count, and, in some centers, viable
CD34+ content. These methods do not account for potential
insults caused by cryopreservation and thawing which may
impact the overall potency. We and others have shown that
post-thaw hematopoietic colony forming units (CFU)
measured on the transplanted product reﬂect potency and
predict engraftment and survival. However, post-thaw CFUs
are not available at the time of CBU selection or trans-
plantation because results are not available for 14 days.
CFUs measured on fresh CB correlate with the number of
cells expressing high levels of the enzyme aldehyde dehy-
drogenase (ALDHbr), suggesting that ALDHbr content could
be a biomarker for potency. To test this, we retrospectively
compared ALDHbrcontent of segments associated with
transplanted CBUs and ALDHbrper kilogram correlated
with engraftment. Therefore, we developed a rapid ALDH-
based potency assay in CBU attached segments that could
be performed when HLA conﬁrmatory typing (CT) was
requested.
Methods: CBUs with attached segments banked at the Car-
olinas Cord Blood Bank and requested for CT between March
2010 and August 2013 were analyzed (n¼2766). Each
segment was thawed and an aliquot of CB was taken for HLA
CT. The remaining CB was washed with 5% dextran/albumin
to remove the DMSO. Samples of 20,000 nucleated cells were
plated in quadruplicate to quantitate CFUs. The number of
viable (7-AAD-), CD45+, ALDHbr, and CD34+ nucleated cells
(glycophorin A-) were measured by ﬂow cytometry using
multiparameter gating.
Results: The number of ALDHbr (Spearman Correlation,
r¼0.81) and [ALDHbr viable CD34+] cells (r¼0.73) both
correlated well with CFUs measured on the segment
(n¼2730 for both analyses). In contrast, CFU correlated less
well with viable CD34+(n¼2727, r¼0.30). These correlations
were valid regardless of time in cryostorage. Of the more
than 2700 units assayed, more than 800 have been admin-
istered to patients. Thus, transplant outcomes data will be
available to compare with laboratory metrics.
Conclusion: We developed a segment-based potency assay
for CBUs selected for CT in a public CB bank. Expression of
ALDH alone and in combination with viable CD34+ best
identiﬁed CBUs with high CFUs content and has potential forTable 1
Case # Age, Sex 1 2 yrs, F 2 6 yrs, M
Reason for SCT BLS 2; MDS
Conditioning Bu/Cy/ ATG Bu/Cy
Stem cell source BM PBSC
%wt gain at onset of SOS 40 9
Bili/Creatinine at initiation of CVVH (mg/dl) 14/3.1 2.3/1.6
SOS onset post SCT (days) 10 6
Mechanical ventilation (MV) or O2 support MV MV
CVVH duration (days) 0.5 5
CVVH ﬁlter M60 M60
CVVH anticoagulation Heparin Citrate
Duration without clot (days) 0.5 3
Deﬁbrotide No No
Outcome Died (day 1) CR*
BLS II e bare lymphocyte syndrome type II
* CR ¼ US liver and serum bilirubin returned to normal;use as a biomarker of potency. Viable CD34+ alone was not
predictive of potency. Further analyses correlating these re-
sults with engraftment are in progress.SUPPORTIVE CARE
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Role of Early Initiation of Continuous Veno-Venous
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Obstructive Syndrome (SOS) Following Stem Cell
Transplant (SCT)
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Introduction: SOS, a syndrome characterized by hepatic si-
nusoidal obstruction, is a frequent cause of acute kidney
injury (AKI) following SCT. In this setting, mortality rates are
>90% despite aggressive therapy. While deﬁbrotide has
emerged as a therapeutic option for many patients with SOS,
managing ﬂuid overload (FO) and electrolyte and acid base
balance in the context of AKI remains a signiﬁcant challenge.
Objective: We retrospectively reviewed our effort to stan-
dardize our approach in patients with AKI and FO due to SOS
following SCT.
Methods: From 9/11 to 9/13, 44 SCT were performed. Six
(13.6%) developed AKI and FO related to SOS. All patients
were treated with ﬂuid/sodium restriction and diuretics
prior to initiation of CVVH. Early indications for CVVH
included diuretic-resistant FO >5% and oligo/anuric AKI. We
performed 57 CVVH procedures (procedure ¼ 24 hours)
with pre and post dilution using citrate or heparin
anticoagulation.
Results: (Table 1) Four of six patients (66%) had complete
recovery (CR) of SOS symptoms (mean recovery time 5 days).
CVVH was initiated within 16 hrs after diagnosis of FO or
oligo/anuric AKI. Mean time on CVVH was 9 days. The me-
dian patency of the CVVH tubing set was 3.5 days. Deﬁbro-
tide was used in 50% of patients. Citrate anticoagulation was3 16 yrs, M 4 12 yrs, F 5 17 yrs, M 6 15 yrs, M
CML AML MDS AML
Bu/Cy/ ATG Bu/Cy/ ATG Bu/Cy/ ATG Bu/Cy/ ATG
D-UCB BM PBSC BM
5 10 20 10
12/3.6 2.6/1.1 2.1/1.0 1.9/2.4
7 11 19 20
O2 O2 MV MV
9 15 16 12
M60/M100 M60 M100 M100
Citrate Citrate Citrate/ Heparin Citrate/ Heparin
4 5 4 6
Yes Yes Yes No
CR CR Died (day 21) CR
